RE:Appoints Matthew J. Pietras as CFO and COO
sounds like a very experienced addition to SZLS management team. More to come. "StageZero Life Sciences is at an exciting and important turning point in its history," said Pietras. "The planned acquisition and integration of Care Oncology promises to be transformative and will provide the Company with multiple revenue streams. I am looking forward to leveraging my financial and operational experience to help the management team position StageZero Life Sciences for long-term growth and profitability."
Pietras brings two decades of financial executive experience, primarily at life science companies. Prior to joining StageZero Life Sciences, he was Vice President of Finance at Maryland-based CiVi Biopharma, where he was responsible for the oversight of Finance and Operations. Prior to that, he was Corporate Treasurer and Controller of Viela Bio from 2017 through 2019. At Viela Bio, the spin-out of AstraZeneca's AutoImmune Franchise, he was responsible for the design and implementation of the financial operations and preparing the company for its eventual IPO. From 2013 through 2017, he held senior finance roles at AstraZeneca/Medimmune, culminating in his position as Global Therapeutic Area Finance Director for the company's Oncology portfolio. He also held finance roles at Wells Fargo, Wachovia, and KPMG. He holds a B.S. in accounting and a B.S. in international business from Pennsylvania State University, and an M.S. in biotechnology and an MBA from Johns Hopkins University. Pietras is also a Certified Public Accountant.
Matt Pietras CFO background - extensive
Quite the bio for Matt Pietras:
He comes to Stagezero from the position of VP of Finance for CiVi Biopharma
CiVi Biopharma is a privately held company that was founded in 2017.
To date, the Company has raised approximately ~$120 million and is supported by leading venture and corporate investors, including Boxer Capital, Tang Capital, Roche Ventures, RA Capital and a leading NYC-based biotechnology investment fund.
RE:RE:RE:Appoints Matthew J. Pietras as CFO and COO
Bottom line is that we will need an infusion of clients seeking cancer diagnosis/treatment to replace the covid revenue which will dwindle away. Fresh thiking on the SZ board will not hurt this cause but revenue will determine the future of this company and right now its al about CARE and telehealth.
Mykndrsn wrote:The Care acquisition will bring an infusion of talent to SZLS as well.